

## Prevention & Treatment of Hepatitis and Chronic Liver Disease

**Raleigh-Durham, NC – October 1-2, 2021**

<b>Conference Location</b>	<b>Sheraton Imperial Hotel</b> 4700 Emperor Boulevard Durham, NC 27703	<b>Phone: (919) 941-5050</b>  <a href="http://www.sheratonrtp.com">http://www.sheratonrtp.com</a>
----------------------------	--	---

**Parking at the Conference** Complimentary parking has been arranged for all seminar participants.

**Driving Directions**

**From East or West**

- Follow Interstate 40 to Exit 282 (Page Road).
- Follow the exit on Page Road and the hotel will be at the top of the hill on the left

**From the South:** Follow Interstate 95 North to Interstate 40 West.

- Travel on I-40 west to Exit 282 (Page Road).
- Turn right onto Page Road and then turn left at the first light.
- The hotel is approximately one quarter of a mile ahead on the left.

**From the North -** Follow Interstate 85 to State Highway 15/501 (Exit 174B).

- Take highway 15/501 to 147 Durham Freeway (Exit 108B); proceed to Interstate 40 East.
- Continue on I-40 east to Exit 282 (Page Road).
- At the end of the exit ramp, proceed through the light. The hotel will be on the left

**Seminar Agenda and Syllabus Information** Registration begins at **12:30 pm** in the **Auditorium**. Please check signage for any last-minute room changes.

The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the *App* will be provided to participants in advance of the seminar. Wi-Fi will be available without charge.

<b>Day 1</b> 12:00 -1:00pm	<b>Registration and View Exhibits</b>
1:00 pm	<b>Opening Comments and Pre-Test</b>
1:15 pm	<b>Viral Hepatitis, Discovery of HCV and Its Natural History</b>
2:00 pm	<b>Hepatitis C: Update on Diagnostics</b> <b>Hepatitis C: Update on Treatment</b>
3:00 pm	<b>Break and View exhibits</b>
3:15 pm	<b>Hepatitis B: Epidemiology, Natural History and Testing</b>
3:45 pm	<b>Anti-viral Therapies for HBV</b>
4:40pm	<b>Delta Hepatitis and Hepatitis E Update from AASLD and EASL</b> <b>Case Studies 1 and 2 –HIV/HCV Co-infection; Infections in persons who inject drugs.</b>
5:10 pm	<b>Product Presentation, Exhibitor Showcase and Reception</b>

6:30 pm	<i>Day 1 concludes</i>
<b>Day 2</b> 7:30 am	<b>Breakfast and View Exhibits</b>
8:00 am	<b>End Stage Liver Disease: Treatment, Managing Complications and Transplant Liver Transplantation</b> <b>Case Study 3 – Cirrhosis and Encephalopathy</b>
8:55 am	<b>Hepatocellular Carcinoma (HCC)</b>
9:25 am	<b>Hepatocellular Carcinoma: New Systemic Treatment Options</b> <b>Case Study 4– Diagnosis and Treatment of Hepatocellular Carcinoma</b>
10:15 am	<i>Break &amp; View Exhibits</i>
10:30 am	<b>Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis</b>
11:15 am	<b>Viral Hepatitis Updates</b> <ul style="list-style-type: none"> <li>• The reemergence of Hepatitis A and Alcoholic liver disease</li> </ul>
11:45 am	<b>SARS-COV-2 in Liver Disease</b>
12:15 pm	<i>Luncheon Presentation</i>
1:15 pm	<b>NAFLD, LAL-D and NASH</b>
2:10 pm	<i>Break &amp; View Exhibits</i>
2:25 pm	<b>NASH Treatments in Practice and in Development</b>
3:30 pm	<b>Closing Comments, Post-test and Wrap-Up</b> Program adjourns at 3:45pm

**Attendee Cancellation, Substitution, Refund**

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

**Recording and Photography**

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

**Attendance Policies**

**Guest Attendance**

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

**Conference Modification or Cancellation**

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

**CME Information**

**Physicians (MD/DO)** - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses** - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-22-1205. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

**Your  
Seminar  
Faculty**



**A. SIDNEY BARRITT, IV, MD, MSCR, FACGA**

Sidney Barritt received his medical degree from University of Virginia School of Medicine in Charlottesville after graduating with a BA in History from the University of Virginia. Later, Dr Barritt continued his education studying Epidemiology and receiving a Master's of Science in Clinical Research degree at the Gillings School of Global Public Health, University of North Carolina-Chapel Hill.

Dr. Barritt is certified in Internal Medicine, Gastroenterology and Transplant Hepatology. Clinically, Dr. Barritt is interested in non-alcoholic fatty liver disease and liver transplant outcomes research. He participates in clinical and diagnostic trials and collaborates with research partners in the UNC school of Pharmacy and School of Public Health.



**ANDREW JOSEPH MUIR, MD, MHS, FAASLD, AGAF**

Dr. Andrew Muir is a gastroenterologist whose research activities are focused on developing innovative treatments for a variety of liver diseases. He has particular interests include viral hepatitis, primary sclerosing cholangitis, and liver transplantation. He also has a longstanding interest in healthcare disparities.

Dr. Muir attended medical school at Duke University. He went on to complete his internal medicine residency and gastroenterology fellowship at Duke, and he also served as chief resident at the Durham Veterans Administration Medical Center. Dr. Muir joined the faculty in the Division of Gastroenterology at Duke in 2000 and assumed the leadership of the Gastroenterology and Hepatology Research program at DCRI in 2010



**ELIZABETH K. GOACHER, PA-C**

Elizabeth K Goacher is a Physician Assistant Specialist in Durham, North Carolina. She graduated with honors from Duke University School Of Medicine in 1998. Having more than 19 years of diverse experiences, especially in treating patients with liver and other GI diseases.

She is affiliated with many hospitals including Duke University Hospital, Duke Health Raleigh Hospital, Duke Regional Hospital, and cooperates with other doctors and specialists in medical group Private Diagnostic Clinic.

---